The Traveler’s Diarrhea drugs in development market research report provides comprehensive information on the therapeutics under development for Traveler’s Diarrhea, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Traveler’s Diarrhea. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Traveler’s Diarrhea and features dormant and discontinued products.
GlobalData tracks ten drugs in development for Traveler’s Diarrhea by nine companies/universities/institutes. The top development phase for Traveler’s Diarrhea is preclinical with five drugs in that stage. The Traveler’s Diarrhea pipeline has seven drugs in development by companies and three by universities/ institutes. Some of the companies in the Traveler’s Diarrhea pipeline products market are: Lumen Bioscience, Cosmo Pharmaceuticals and Institute of Medical Science The University of Tokyo.
The key targets in the Traveler’s Diarrhea pipeline products market include Cystic Fibrosis Transmembrane Conductance Regulator, DNA Directed RNA Polymerase Subunit Beta, and Flagellin.
The key mechanisms of action in the Traveler’s Diarrhea pipeline product include Cystic Fibrosis Transmembrane Conductance Regulator Blocker with one drug in Preclinical. The Traveler’s Diarrhea pipeline products include one routes of administration with the top ROA being Oral and seven key molecule types in the Traveler’s Diarrhea pipeline products market including Monoclonal Antibody, and Small Molecule.
Traveler’s Diarrhea overview
Traveler’s diarrhea occurs within 10 days of travel to an area with poor public hygiene. The most common illness in travelers, it is caused by drinking water or eating food that contains bacteria, viruses, or parasites. Most traveler’s diarrhea is from bacteria. It often goes away in a few days. Often, the only treatment is fluid replacement.
For a complete picture of Traveler’s Diarrhea’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
